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Human Disc large tumor suppressor (DLG1) participates in regulating cell polarity and 30 
proliferation, suggesting an important connection between epithelial organization and cellular 31 
growth control. However, it was demonstrated that DLG1 could acquire oncogenic attributes 32 
in some specific contexts. In this work, we evaluated the expression of DLG1 and its 33 
contribution to the progress of cervical lesions in order to investigate a potential role of this 34 
polarity protein in human oncogenic processes. 35 
We analyzed cervical biopsies from women with low-grade squamous intraepithelial lesion 36 
(LSIL) diagnosis (n=30), for DLG1 expression by immunohistochemistry. These results were 37 
correlated with the clinical monitoring of the patients during a 24-month follow-up period. 38 
Our data indicate that while all LSIL patients with a DLG1 staining pattern similar to normal 39 
tissues are significantly more likely to regress (n=23, Pattern I), all LSIL biopsy specimens 40 
showing a diffuse and intense DLG1 staining likely progress to high-grade lesions (n=4, 41 
Pattern II). Finally, all persistent LSIL analyzed showed an undetermined DLG1 staining, 42 
with a diffuse distribution without a strong intensity (n=3, Pattern III). We found a significant 43 
association between the expression pattern of DLG1 and the evolution of the lesion 44 
(p<0.00001). 45 
This work contributes to the knowledge of DLG1 biological functions, suggesting that its 46 
expression may have an important role in the progression of early dysplastic cervical lesions, 47 
giving prognostic information. 48 
 49 
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1. Introduction 54 
DLG1, the human homologue of Drosophila disc large tumor suppressor, is a multi-PDZ 55 
(PSD, DLG1, ZO-1) domain-containing protein that belongs to the family of molecular 56 
scaffolding proteins known as membrane associated guanylate kinases (MAGUKs). DLG1 is 57 
a component of the Scribble polarity complex which participates in regulating cell polarity 58 
and proliferation, suggesting a key connection between epithelial organization and cellular 59 
growth control (Assemat et al., 2008), (Roberts, 2012). An abnormal expression of DLG1 has 60 
been reported in several cancer types, with a loss of DLG1 expression associated with 61 
complete lack of cell polarity and tissue architecture during the latest stages of malignant 62 
progression, thereby defining DLG1 as a potential tumour suppressor (Facciuto et al., 2012), 63 
(Sugihara et al., 2016). 64 
In addition, the most compelling evidence of DLG1 oncosuppressor activity in humans was 65 
its identification as a target of several viral oncoproteins: Human papillomavirus (HPV) E6, 66 
Human T cell leukemia virus type 1 Tax, and Adenovirus type 9 E4-ORF1 (James and 67 
Roberts, 2016). However, recent studies have demonstrated that DLG1 can acquire oncogenic 68 
attributes in some specific contexts; highlighting the importance of DLG1 deregulation in 69 
human carcinogenesis (Roberts, 2012). 70 
On the other hand, cervical cancer is one of the most common cancers affecting women 71 
worldwide, and is responsible for an estimated 530,000 new cases with a mortality 72 
approaching 50% each year (Parkin, 2006) (Lowndes, 2006), (de Freitas et al., 2014). 73 
Furthermore, over 85% of these episodes occur in developing countries due to inadequate 74 
prevention and control programs (Frazer, 2004) (WHO/ICO, 2010). It has been confirmed 75 
that high-risk HPV persistent infection is the main pathogenic factor for the development of 76 
cervical cancer (zur Hausen, 2002). The main clinical stages in cervical carcinogenesis 77 
include HPV infection, persistence, progression to precancerous lesions and invasion. Thus, 78 
invasive cervical cancer is preceded by a progressive spectrum of cervical intraepithelial 79 
neoplasia (CIN), also termed squamous intraepithelial lesion (SIL) (Darragh et al., 2012). 80 
Therefore, it is one of the few preventable human cancers and its prevention is based on 81 
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vaccination and early diagnosis of the precancerous lesions (Arbyn et al., 2011; Bratic et al., 82 
2016). SIL is an heterogeneous group graded as either low-grade (LSIL) or high-grade 83 
squamous intraepithelial lesions (HSIL), depending on the severity of their histological 84 
epithelial abnormalities (Doorbar et al., 2012). However, not all HPV infections give rise to 85 
cervical dysplasia and promote its progression to carcinoma. On the contrary, it is well known 86 
that most LSIL are transient and regress spontaneously to normal epithelium in 1-2 years 87 
(Schiffman et al., 2007), and only a small fraction of these lesions are expected to progress to 88 
HSIL and, eventually, to invasive cervical cancer (Quint et al., 2013). Thus, the identification 89 
of biomarkers that can predict the chance of progression or regression of these early lesions, 90 
could represent a major contribution to the clinical management of patients at high risk to 91 
progress to cancer.  92 
A more complete understanding of the factors involved in progression to cancer may lead to 93 
new paradigms for the efficient monitoring of cervical diseases. In regard to this, the proper 94 
establishment and maintenance of cell polarity is essential for normal epithelium physiology 95 
and loss of this polarity and tissue organization is a hallmark of cancer development (Martin-96 
Belmonte and Perez-Moreno, 2011). In this work, we focused on the analysis of the 97 
expression of DLG1 polarity protein and its contribution to the progress of cervical lesions, in 98 
order to elucidate a potential role of the polarity proteins in cervical oncogenic processes. 99 
In previous studies we and other groups evaluated the differential expression of DLG1 during 100 
the progression to malignancy in cervical lesions by immunohistochemistry (IHC) (Watson et 101 
al., 2002; Cavatorta et al., 2004; Lin et al., 2004). Interestingly, while a marked reduction of 102 
DLG1 levels in invasive carcinomas was described, a high overexpression and changes in 103 
DLG1 distribution at earlier stages of the cervical carcinogenic process were observed 104 
(Cavatorta et al., 2004). Specifically, LSIL samples showed a marked variability in their 105 
DLG1 staining with two different archetypes according to the DLG1 expression patterns. One 106 
of such archetypes comprised samples where both DLG1 level and distribution, within the 107 
different strata of the squamous epithelium, were quite similar to those observed in normal 108 
epithelium. The other subset of LSIL biopsies presented an over expression of DLG1 109 
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throughout the full thickness of the epithelium, with a preferentially cytoplasmic localization 110 
similar to the pattern obtained for HSIL specimens (Cavatorta et al., 2004). Therefore, given 111 
the characteristics of DLG1 and its likely involvement in both tumour suppression and 112 
oncogenic processes, it is interesting to investigate whether these different patterns of 113 
expression may provide information about the potential progression and / or regression of 114 
LSIL. For this, we analyzed the immunohistochemical detection of DLG1 polarity protein and 115 
its association with the course of SIL. We evaluated uterine cervical biopsies from women 116 
with LSIL diagnoses, and the DLG1 immunohistochemistry results were correlated with the 117 
clinical monitoring during the follow-up period.  118 
 119 
2. Materials and Methods 120 
2.1. Patient samples 121 
All experiments were undertaken with the written informed consent of each subject, and we 122 
received study approval from the ethics committee of the Hospital Provincial del Centenario, 123 
Rosario, Argentina. Fifty-two patients with an established diagnosis of LSIL via a 124 
colposcopy-directed biopsy and without previous history of cervical lesion were randomly 125 
selected from the Lower Genital Tract Diseases and Gynecologic Oncology Section, Service 126 
of Gynecology, Hospital Provincial del Centenario, Rosario, Argentina. 127 
All tissue samples were fixed in 10% buffered formalin, routinely processed and embedded in 128 
paraffin. Biopsies were collected from the bank of paraffin-embedded tissue sections of the 129 
Cátedra de Anatomía y Fisiología Patológicas and the histological diagnoses were established 130 
using morphologic criteria based on H&E stained sections. 131 
Patients were grouped according to their outcome during the 24-month follow-up and clinical 132 
information was obtained from the patients’ medical record. The final outcome of LSIL was 133 
classified as regression, persistence and progression according to the following criteria: i) 134 
Regression: concomitant negative cervical smear (Papanicolaou test, PAP test) and/or 135 
negative biopsy observed at any time during the follow-up and confirmed at 24-month 136 
follow-up; ii) Persistence: LSIL was diagnosed on the basis of either 1 or more cytologies and 137 
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biopsies of LSIL diagnosis during the follow-up; iii) Progression: appearance of a 138 
histologically confirmed high-grade lesion at any time during the follow-up.  139 
Gynecology oncologists followed up the LSIL patients by cytology and colposcopy exams 140 
with check-up every 6 months for at least 2 years. When a PAP test presented a higher-grade 141 
lesion or suspicious colposcopy images were observed, the gynecologist confirmed this with a 142 
new biopsy. If the lesion progressed during the follow-up, the patient received proper 143 
treatment.  144 
 145 
2.2. Immunohistochemistry  146 
The procedures were performed as previously described (Cavatorta et al., 2004) (Gardiol et 147 
al., 2006). Briefly, sections (5 m) were cut from paraffin-embedded tissue blocks and 148 
mounted on pretreated glass. After deparaffinizing with xylene, the slides were rehydrated 149 
using a graded alcohol series. Endogenous peroxidase activity was blocked by immersing 150 
sections in 3% hydrogen peroxide in methanol for 20 min. Sections were placed in 0.1 M 151 
citric acid (pH 6) and heated for 12 min on high power using a conventional microwave oven, 152 
to facilitate antigen retrieval. After blocking nonspecific binding by addition of normal horse 153 
serum (Vectastain ABC Kit; Vector, Burlingame, CA, USA) for 40 min, sections were 154 
incubated overnight with the primary anti-DLG1 mouse monoclonal antibody diluted at 1:20 155 
(clone 2D11, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C. For detection, 156 
samples were treated successively with biotinylated secondary antibody for 30 min and with 157 
avidin–biotin peroxidase complex for a further 30 min at room temperature (DAKO, 158 
Denmark). The reaction was developed using a diaminobenzidine chromogenic substrate kit 159 
for peroxidase (Vector), and sections were counterstained with haematoxylin. Negative 160 
controls were processed as described, except that primary antibody was omitted. Specimens 161 
were visualized and photographed using a Zeiss Primo Star light microscope (Zeiss, 162 
Germany). 163 
 164 
2.3. Evaluation of immunohistochemical staining results 165 
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The DLG1 staining was graded as either ‘‘no overexpression’’ (similar to normal samples, 166 
called Pattern I), ‘‘overexpression’’ (moderate to strong cytoplasmic staining intensity with 167 
diffuse distribution, called Pattern II), or “undetermined” (diffuse distribution without a 168 
strong intensity, called Pattern III)  169 
 170 
2.4. Statistical analysis 171 
Statistical analysis of categorical variables was performed by Fisher’s test. A p-value of 0.05 172 
or less was considered to indicate statistical significance. 173 
 174 
3. Results  175 
This study began with 52 patients of reproductive age (mean, 24 years) with a cervical biopsy 176 
specimen that confirmed the LSIL diagnosis. Twenty-two cases were discarded because some 177 
of them did not have residual lesion upon subsequent paraffin block cuts and others did not 178 
complete the follow-up process. Therefore, 30 patients with a LSIL biopsy were finally 179 
included in this analysis. Out of these patients, 23 (76.7%) regressed, 3 (10%) persisted, and 4 180 
(13.3%) progressed to HSIL, according to their outcome within the 2-years of follow-up. This 181 
concurs with current data in the literature that estimates that only 10% to 15% of LSIL evolve 182 
to high-grade lesions (Schiffman et al., 2007; Wright et al., 2007).  183 
DLG1 immunostaining results showed that from the 23 LSIL cases that regressed to a 184 
normalization of the epithelium during their follow-up routine, the DLG1 expression in the 185 
initial biopsy presented a pattern quite similar to that observed for normal tissue in our 186 
previous report (Cavatorta et al., 2004). In normal samples DLG1 was expressed in the basal, 187 
parabasal and intermediate layers of the stratified cervical epithelium but it was absent in the 188 
uppermost-differentiated cellular strata. DLG1 was localized preferentially in the cytoplasm 189 
of basal cells, but in the parabasal and intermediate areas it was also present at regions of cell-190 
cell contact. Nuclear localization of DLG1 was additionally observed (Fig. 1a). These results 191 
indicate that LSIL with a DLG1 staining pattern similar to that of normal tissue (Pattern I) are 192 
significantly more likely to regress. However, in these cases the basal cells showed a marked 193 
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decrease of DLG1 staining when compared with normal samples. Figures 1b and 1c show the 194 
DLG1 staining both in the initial and final biopsies, corresponding to a representative LSIL 195 
patient (Fig. 1b) who regressed to a normal cervical epithelium (Fig. 1c). This final sample, 196 
consistent with a normalization of the epithelium, exhibited the typical cell border DLG 197 
localization in suprabasal layers of normal epithelium (Fig. 1c).  198 
On the other hand, the four patients (4/30, 13.3%) that experimented a progression to a high-199 
grade lesion, expressed a diffuse and very intense DLG1 staining throughout the full 200 
thickness of the epithelial strata, with a predominant cytoplasmic distribution and loss from 201 
cell contacts (Pattern II). This result indicates an up-regulation of DLG1 levels together with 202 
a sub-cellular relocalization, archetype that corresponds to that observed for HSIL specimens 203 
in our previous study (Cavatorta et al., 2004) (Fig. 2a). Figures 2b and 2c show the DLG1 204 
staining both in the initial and in the final biopsy respectively, corresponding to a 205 
representative LSIL condition (Fig. 2b) that progressed to HSIL (Fig. 2c) during the follow-206 
up. In this case both specimens presented a very strong DLG1 immunostaining throughout the 207 
epithelium.  208 
Finally, when we analyzed the 3 LSIL persistent specimens, the pattern of the DLG1 staining 209 
was diffuse comparing with the normal tissue but they did not show a clear overexpression 210 
like those progressing to HSIL (Pattern III, undetermined) (Supplementary Fig. S1). 211 
It is important to notice that this study examined a low number of samples. However, the data 212 
from this pilot investigation clearly indicate that while all LSIL patients with a DLG1 staining 213 
pattern similar to normal tissues rarely progress, all LSIL biopsy specimens showing a diffuse 214 
and very intense DLG1 staining are significantly more likely to progress to high-grade 215 
lesions. In fact, we found a significant association between the expression of DLG1 and 216 
evolution of the lesion (p<0.00001) (Table 1).  217 
 218 
4. Discussion 219 
Malignant transformation in many carcinomas is associated with failure in the establishment 220 
and maintenance of epithelial cell polarity. These features are seen in early dysplastic cervical 221 
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lesions and during their progression to cancer (Watson et al., 2002; Cavatorta et al., 2004, Lin 222 
et al., 2004) . In the current study, we focused on the involvement of DLG1 polarity protein in 223 
cervical cancer development analyzing biopsies from women with diagnoses of LSIL by IHC. 224 
The results have been related to the diagnosis and monitoring of patients during the 24-month 225 
follow-up. Remarkably, our findings showed that all LSIL biopsy specimens from patients 226 
who progressed to HSIL presented an overexpression of DLG1 throughout the full thickness 227 
of the epithelium, with a preferentially cytoplasmic localization. Accordingly, all LSIL biopsy 228 
specimens that showed a DLG1 expression pattern similar to that observed in normal tissue 229 
regressed spontaneously to normal epithelium.  230 
Some possible explanations for these observations are related to the fact that the mechanisms 231 
that control DLG1 expression at transcriptional (transcription factors) or post-transcriptional 232 
(splicing, phosphorylation and ubiquitinylation) levels are de-regulated during transformation 233 
by still unknown pathways (Facciuto et al., 2012). It is also possible that in neoplastic cells, 234 
the normal protein interactions that localize DLG1 at cell borders were disrupted, and novel 235 
unidentified binding partners of DLG1 could then promote its redistribution to the cytoplasm 236 
resulting in a change of function. In fact, the accumulation of DLG1 in the cytoplasm may 237 
have an oncogenic significance, since it was shown that specific sub-cellular pools of DLG1 238 
could gain oncogenic functions in the presence of viral oncoproteins (Frese et al., 2006) 239 
(Krishna Subbaiah et al., 2012). In this sense, and in agreement with the present study, we 240 
have recently reported that high risk HPV-18 E6 and E7 oncoproteins induce a clear increase 241 
in DLG1 abundance and a striking cellular redistribution from the cell contacts to the 242 
cytoplasm using organotypic models that in vitro mimic the epithelial tissue (Valdano et al., 243 
2016). Thus, even though DLG1 has been recognized as a potential oncosuppressor, the 244 
mislocalization of DLG1 found in premalignant cervical lesions could have acquired 245 
oncogenic traits, contributing to the early stages of cancer development. This concept can be 246 
extrapolated to non-viral-associated epithelial tumours, where DLG1 overexpression and 247 
mislocalization were also reported (Facciuto et al., 2012). 248 
This study is in line with previous reports about the value of p16INK4a (p16) expression as a 249 
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prognostic marker for LSIL lesions. The increased level in p16 protein, a key oncosuppressor 250 
regulating cell proliferation, has been identified as a diagnostic indicator for transforming 251 
HPV infections. Moreover, a recent report has shown that another MAGUK protein that 252 
maintains the architecture of cell junctions, MAGI-2 (WW and PDZ domain containing 253 
protein 2), is elevated in prostate cancer, underlining the possible role of these PDZ proteins 254 
in oncogenic processes (Goldstein et al., 2016).  255 
As mentioned before, cervical cancer is associated with high-risk HPV infections and there 256 
are some reports showing that different HPV types differentially target DLG1 protein 257 
(Thomas et al., 2005). In this regard, there are some possible limitations in this study since no 258 
HPV typing data were available. Therefore, the potential correlation among DLG1 staining, 259 
specific HPV type and progression of LSIL could not be determined. However, previous 260 
studies using a low number of samples (Cavatorta et al., 2004; Lin et al., 2004) showed that 261 
DLG1 staining in cervical lesions did not vary in relation to the associated HPV types. This 262 
issue suggests that in cervical samples HPV type may not influence the level and cell/tissue 263 
distribution of DLG1.  264 
LSIL are lesions of uncertain behavior, and no histological criteria allow a differentiation 265 
between cases that progress or return, though complementary assays to predict the future may 266 
contribute to a prophylactic intervention in patients at high risk, avoiding unnecessary 267 
treatment. Despite the importance of such tools for clinical practice, the study and 268 
implementation of prognostic markers as part of the gynecological triage are scarce. In this 269 
regard and even though the number of samples included in this study is limited, the results 270 
obtained suggest that DLG1 staining would be a promising candidate. While previous 271 
published investigations described DLG1 expression in cervical biopsies (Watson et al., 2002; 272 
Cavatorta et al., 2004, Lin et al., 2004), this is the first report that associates the staining of 273 
DLG1 at the moment of LSIL diagnosis with the eventual progression or regression of the 274 
lesion during the 24 months clinical follow-up. Nevertheless, further studies with larger 275 
cohorts are encouraged to confirm our present findings and to identify it potential use as a 276 
prognostic biomarker.  277 
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In conclusion, this work contributes to understand the involvement of DLG1 polarity protein 278 
in human cancer progression, showing that DLG1 expression patterns may associate with 279 
disease progress in cervical lesions.  280 
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Legends to Figures and Tables 378 
Fig. 1: Detection of DLG1 expression assessed by immunohistochemistry in the 379 
squamous epithelium of the cervix. a) Expression of DLG1 in normal cervical epithelium. 380 
Black arrows indicate the localization of DLG1 at cell-cell contact; b) DLG1 staining of an 381 
area of LSIL in a patient who regressed to a negative result of the PAP test and negative 382 
biopsy. c) DLG1 immunostaining in the final biopsy showing regression to normal 383 
epithelium. Scale bars = 100 μm. 384 
 385 
Fig. 2: Analysis of DLG1 expression assessed by immunohistochemistry in the squamous 386 
epithelium of the cervix. a) Expression of DLG1 in HSIL. b) DLG1 staining of an area of 387 
LSIL in a patient who progressed to HSIL. c) DLG1 immunostaining in the final biopsy 388 
showing progression to HSIL. Scale bars = 100 μm. 389 
 390 
Table 1: DLG1 Immunostaining vs Follow-up Status. After applying Fisher's exact test it 391 
is concluded that there is a significant association (p <0.00001) between DLG1 expression 392 
and the evolution of the lesion. 393 
 394 
  395 
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Tables 396 




 DLG1 immunostaining  
 Pattern I Pattern II Pattern III  
Regression 23 0 0 
Persistence 0 0 3 
Progression 0 4 0 
Number of 
Samples  
 23 4 3 
 398 
 399 
